As our aging population continues to grow, Medicare Parts B and D will play an increasingly important role in providing access to lifesaving medicines for tens of millions of Americans. And ensuring timely, affordable access to new medicines for seniors has never been more vital as we enter the age of curative therapies and disease-modifying treatments for debilitating conditions.
“It's really not an overstatement to say we're in the golden era of medicine,” noted Stephen J. Ubl, president and CEO of PhRMA, in a discussion with the Alliance for Health Policy’s President and CEO, Sarah Dash. But, as Dash pointed out, “did our system grow up in a way that is going to be able to afford it?”
To discuss how we can evolve Medicare to enable affordable access to tomorrow’s promising science, Ubl and Dash were joined by policymakers and other health care thought leaders in a recent event hosted by The Atlantic and sponsored by PhRMA, titled The State of Care: Future of Medicare.